Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by healthstock1234on Aug 13, 2015 12:40am
127 Views
Post# 24013693

Canaccord Genuity-buy for CXRX(US)-Nasdaq,price target $95

Canaccord Genuity-buy for CXRX(US)-Nasdaq,price target $95https://www.markets.co/canaccord-genuity-reiterates-a-buy-rating-on-concordia-healthcare/
In a report released today, Neil Maruoka from Canaccord Genuity reiterated a Buy rating on Concordia Healthcare (NASDAQ: CXRX), with a price target of $95. The company’s shares opened today at $77.91.

According to TipRanks.com, Maruoka is a 4-star analyst with an average return of 11.5% and a 66.7% success rate. Maruoka covers the Healthcare sector


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities